Malignant Mesothelioma: Asbestos Exposure

Chapter

Abstract

Asbestos is a recognized high-profile health hazard with an estimated total cancer burden from malignant mesothelioma and lung cancer in industrialized countries to be in the order of 30,000 cancers per year (Tossavainen A, People Work Res Rep. 14: 8–27, 1997) with further deaths related to lung fibrosis (asbestosis) and complications of asbestos-related diffuse pleural thickening. Projections for the 1995–2029 period suggest that male mesothelioma deaths will double over the next 20 years to a peak of 9,000 in 2018 and then decline, with an estimated 250,000 deaths up to 2025 in Europe (Peto J, Decarli A, La Vecchia C et al.. Br J Cancer. 79: 666–72, 1999).

Keywords

Asbestos exposure Asbestos mineralogy Malignant mesothelioma Asbestos type Asbestos fiber counting Pulmonary asbestos analysis 

References

  1. 1.
    Tossavainen A. Asbestos, asbestosis and cancer: exposure criteria for clinical diagnosis. People Work Res Rep. 1997;14:8–27. Helsinki: Finnish Institute of Occupational Health.Google Scholar
  2. 2.
    Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–72.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Willis RA. Pathology of tumors. Washington, DC: Butterworth; 1960. 185.Google Scholar
  4. 4.
    Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317–31.PubMedGoogle Scholar
  5. 5.
    Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma. Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol. 1988;6:147–53.PubMedGoogle Scholar
  6. 6.
    Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718–21.PubMedGoogle Scholar
  7. 7.
    La Vecchia C, Boffetta P. Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma. Eur J Cancer Prev. 2012;21(3):227–30.PubMedCrossRefGoogle Scholar
  8. 8.
    La Dou J. The asbestos cancer epidemic. Environ Health Perspect. 2004;112:285–90.Google Scholar
  9. 9.
    Craighead JE, Gibbs AR, Pooley FD. Mineralogy of asbestos. In: Craighead JE, Gibbs AR, editors. Asbestos and its disease. New York: Oxford University Press; 2008. p. 23–38. Chapter 2.CrossRefGoogle Scholar
  10. 10.
    Bartrip PW. History of asbestos-related disease. Postgrad Med J. 2004;80:72–6.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Browne K. Thresholds of risk. In: Gibbs GW, Dunnigan J, Kido M, Higashi T, editors. Health risks from exposure to mineral fibres. An international perspective. North York: Captus University Publications; 1991. p. 355.Google Scholar
  12. 12.
    Iwatsubo Y, Pairon JC, Boutin C, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case control study. Am J Epidemiol. 1998;148:133–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Gibbs AR, Pooley FD. Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax. 1990;45:649–54.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma; attributable risk of asbestos exposure. Occup Environ Med. 1994;51:804–11.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Roggli VL, Oury TD, Moffatt EJ. Malignant mesothelioma in women. Anat Pathol. 1997;2:147–63.PubMedGoogle Scholar
  17. 17.
    Xu Z, Armstrong BK, Blunsdon BJ, et al. Trends in mortality for malignant mesothelioma of the pleura, and production and use of asbestos in Australia. Med J Aust. 1985;143:185–7.PubMedGoogle Scholar
  18. 18.
    Andersson M, Olsen JH. Trend and distribution of mesothelioma in Denmark. Br J Cancer. 1985;51:699–705.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Mark EJ, Yokoi T. Absence of evidence for a significant background incidence of diffuse malignant mesothelioma from asbestos exposure. Ann N Y Acad Sci. 1991;643:196–204.PubMedCrossRefGoogle Scholar
  20. 20.
    Peterson JT, et al. Non asbestos-related malignant mesothelioma: a review. Cancer. 1984;54:951.PubMedCrossRefGoogle Scholar
  21. 21.
    Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med. 1996;30(3):252–66.PubMedCrossRefGoogle Scholar
  22. 22.
    Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000;44(8):565–601.PubMedCrossRefGoogle Scholar
  23. 23.
    Hodgson JT, et al. The expected burden of mesothelioma mortality in Great Britain from 2002–2050. Br J Cancer. 2005;92(3):587–93.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Berman DW, Crump KS. Final draft: technical support document for a protocol to assess asbestos related risk. US Environmental Protection Agency;2003.Google Scholar
  25. 25.
    Yarborough CM. Chrysotile as a cause of mesothelioma: an assessment based on epidemiology. Crit Rev Toxicol. 2006;36:165–87.PubMedCrossRefGoogle Scholar
  26. 26.
    Stanton MF, Wrench C. Mechanisms of mesothelioma induction with asbestos and fibreglass. J Natl Cancer Inst. 1972;48:797.PubMedGoogle Scholar
  27. 27.
    Stanton MF, Layard M, Tegeris A, Miller E, May M, Morgan E, Smith A. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst. 1981;67:965–75.PubMedGoogle Scholar
  28. 28.
    Pott F, Huth F, Fredericks K. Tumorogenic effect of fibrous dust in experimental animals. Environ Health Perspect. 1974;9:313–5.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Davis JMG, Jones AD. Comparisons of the pathogenicity of long and short fibres of chrysotile asbestos in rats. Br J Exp Pathol. 1988;69:717–37.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Platek F, et al. Chronic inhalation of short asbestos fibres. Fundam Appl Toxicol. 1985;5:327–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Bernstein DM, et al. Comparison of Calidria chrysotile asbestos to pure tremolite: final results of the inhalation biopersistence and histopathology examination following short-term exposure. Inhal Toxicol. 2005;17(9):427–49.PubMedCrossRefGoogle Scholar
  32. 32.
    Bernstein DM, Rogers RA, Sepulveda R, et al. Quantification of the pathological response and fate in the lung and pleura of chrysotile in combination with fine particles compared to amosite-asbestos following short-term inhalation exposure. Inhal Toxicol. 2011;23(7):372–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Higgins ITT, Glassman JH, Oh MS, et al. Mortality of reserve mining company employees in relation to taconite dust exposure. Am J Epidemiol. 1983;118(5):710–9.PubMedGoogle Scholar
  34. 34.
    McDonald JC, Gibbs GW, Liddell DK, et al. Mortality after long exposure to cummintonite-grunerite. Am Rev Respir Dis. 1978;118.Google Scholar
  35. 35.
    Report of Expert Panel on Health Effects of Asbestos and Synthetic Vitreous Fibres: the influence of fibre length. Agency for toxic substances and disease registry. Atlanta; 2003.Google Scholar
  36. 36.
    McDonald JC, et al. Mesothelioma and asbestos fibre type. Evidence from lung tissue analyses. Cancer. 1989;63(8):1544–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Rogers A, Leigh J, Berry G, Ferguson DA, Mulder HB, Ackad M. Relationship between lung asbestos fibre type and concentration and relative risk of mesothelioma. Cancer. 1991;67:1912–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Berman DW. Apples to apples: the origin and magnitude of differences in asbestos cancer risk estimates derived using varying protocols. Risk Anal. 2010;31:1539–6924.Google Scholar
  39. 39.
    Suzuki Y, Yuen SR. Asbestos tissue burden study on human malignant mesothelioma. Ind Health. 2001;39:150–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Suzuki Y, Yuen SR. Asbestos fibres continuing to the induction of human malignant mesothelioma. Ann N Y Acad Sci. 2002;982:160–76.PubMedCrossRefGoogle Scholar
  41. 41.
    Chiappino G. Mesotelioma: Ruyolo Delle Fibre Ultrafini Aire Conseguenti Riflessi In: Campo Preventivo Aire Medico-Legale. Med Lab. 2005;96:3–23.Google Scholar
  42. 42.
    Dodson RF, O’Sullivan MF, Huang J, et al. Asbestos in extra-pulmonary sites – omentum and mesentery. Chest. 2000;117:486–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Boutin C, Dumortier P, Rey F, et al. Black spots concentration oncogenic asbestos fibres in the parietal pleura. Thoracoscopic and mineralogic study. Am J Respir Crit Care Med. 1996;153:444–9.PubMedGoogle Scholar
  44. 44.
    Ontario Royal Commission. The Royal Commission on Matters of Health and Safety Arising from the Use of Asbestos in Ontario. J. Stefan Dupre, J. Fraser Mustard, Robert J. Uffen. Ontario Ministry of the Attorney General. 1983 Three Volumes.Google Scholar
  45. 45.
    Craighead JE, Gibbs AR, Pooley FD. Mineralogy of asbestos. In: Craighead JC, Gibbs AR, editors. Asbestos and its diseases. Oxford: Oxford University Press; 2008. p. 23–38. Chapter 2.Google Scholar
  46. 46.
    Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Roach HD, Davies GJ, Attanoos R, et al. Asbestos: when the dust settles – an imaging review of asbestos related disease. Radiographics. 2002;22:S167–84.PubMedCrossRefGoogle Scholar
  48. 48.
    De Vuyst P, Karjalainen A, Dumortier P, et al. Guidelines for mineral fibre analysis in biological samples: report of the ERS Working Group. Eur Respir J. 1998;11:1416–26.PubMedCrossRefGoogle Scholar
  49. 49.
    Holmes S. Developments in dust sampling and counting techniques in the asbestos industry. Ann N Y Acad Sci. 1965;132:288–97.PubMedCrossRefGoogle Scholar
  50. 50.
    The Asbestos International Association. Reference method for the determination of airborne asbestos fibre concentrations at workplaces by light microscopy (membrane filter method). London: Asbestos International Association; 1979.Google Scholar
  51. 51.
    Walton WH. The natures hazards and assessment of occupational exposure to airborne asbestos dust: a review. Ann Occup Hyg. 1982;25:117–247.PubMedCrossRefGoogle Scholar
  52. 52.
    Gibbs AR, Attanoos RL. Examination of lung specimens. J Clin Pathol. 2000;53:507–12.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Attanoos RL, Gibbs AR. An approach to industrial post mortems. Histopathology. 2009;54(1):134–42.PubMedCrossRefGoogle Scholar
  54. 54.
    Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology. 2008;53(3):340–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Attanoos RL, Gibbs AR. Pseudomesotheliomatous’ carcinomas of the pleura – a 10 year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology. 2003;43(5):444–52.PubMedCrossRefGoogle Scholar
  56. 56.
    Roggli VL, Gibbs AR, Attanoos RL, Churg A, Popper H, Cagle P, Corrin B, Franks T, Galateau-Salle F, Galvin J, Hasleton P, Henderson D, Honma K. Pathology of asbestosis – an update of the diagnostic criteria. Report of the Asbestosis Committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134:462–80.PubMedGoogle Scholar
  57. 57.
    Roggli VL. Chapter 3. In: Roggli VL, Oury TD, Sporn TA, editors. Asbestos bodies and nonasbestos ferruginous bodies pathology of asbestos associated diseases. 2nd ed. Verlag: Springer; 2004; p. 34–70.Google Scholar
  58. 58.
    Pooley FD, Ranson DL. Comparison of the results of asbestos fibre dust counts in lung tissue obtained by analytical electron microscopy and light microscopy. J Clin Pathol. 1986;39:313–7.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Christian A, Pooley FD, Attanoos RL, Gibbs AR. Lung mineral fibre analysis from a National Referral Centre of 402 cases and >4000 fibres – the Cardiff experience in 2006. J Pathol. 2009;221(S1):S8.Google Scholar
  60. 60.
    Tuomi T. Fibrous minerals in the lungs of mesothelioma patients; comparison between data on SEM, TEM and personal interview information. Am J Ind Med. 1992;21:155–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of Cellular PathologyUniversity Hospital of WalesCardiffUK

Personalised recommendations